420P Predictive value of systemic inflammation for clinical complications

Systemic inflammation is a known hallmark of cancer and the prognostic role of inflammatory markers in lung cancer is well-established. However, their potential predictive value for clinical complications remains largely unexplored. The goal of the study presented by Ilann Oueslati during ELCC 2025 was therefore to assess whether baseline values and dynamic changes in serum inflammatory scores are predictors of lung cancer clinical complications.

Out of 241 patients included in the study, 172 experienced complications during the follow-up period (mainly ER visits). The most frequent diagnostic categories were infectious, cardiovascular and digestive. Interestingly, multiple inflammatory markers and scores proved to be significant baseline and dynamic predictive factors for clinical complications. For example, both the Glasgow Prognostic Score and the modified Glasgow Prognostic Score were identified as significant independent predictors, while the serum albumin level was found to be an independent protective predictive factor. As such, these routinely measured variables could be used to develop a clinical score to stratify the risk of adverse events for all lung cancer patients undergoing systemic treatment.